Background & Summary {#Sec1}
====================

Cystic fibrosis (CF) is considered one of the most common genetic diseases, affecting 1 in 2500--3500 live births in Caucasian populations^[@CR1]^. Over 1500 mutations have been previously reported in the *CFTR* gene. Due to the high carrier rates, the American College of Obstetricians and Gynecologists (ACOG) suggests CF carrier testing for all women who are considering pregnancy or are currently pregnant^[@CR2]--[@CR4]^. In 2004, the American College of Medical Genetics and Genomics (ACMG) published a guideline on testing 23 *CFTR* mutations with high carrier frequencies across different ethnicities^[@CR3]^. However, to increase the detection rate, it has become a common practice for clinical laboratories to expand the *CFTR* panel to more than 100 mutations, and even full gene analysis^[@CR5]--[@CR7]^.

In the past three decades, the detection of *CFTR* mutations has evolved through various molecular methods, including reverse dot blot, restriction fragment length polymorphism (RFLP), and Sanger sequencing^[@CR8],[@CR9]^. The advent of next generation sequencing (NGS) leads to a higher clinical sensitivity by screening more targeted *CFTR* mutations and sequencing of the exonic gene regions, as well as a higher throughput by multiplexing many samples into one sequencing run^[@CR10],[@CR11]^. While NGS excels at generating large amount of data, it is time-consuming and less cost-effective for sequencing few targets and low volume of samples. Recently, Swift Biosciences released a pre-designed amplicon/library preparation kit that can amplify the *CFTR* gene using 87 amplicons in one reaction. Combined with Illumina MiSeq Nano kit v2 (300-cycles), this protocol allows for quick turnaround time, low sample volume, and cost effectiveness.

While a previous study had demonstrated that this method could detect frequent and rare *CFTR* mutations when compared to other methods, the technical specifications were not analysed^[@CR12]^. Here we examine the Accel-Amplicon CFTR Panel using CF-positive samples by assessing the performance of this assay. We processed seven CF-positive samples that represent across the *CFTR* mutation spectrum (missense, nonsense, splicing and indels), and these mutations are recommended in the ACMG guideline^[@CR3]^. The first run included one normal sample and three CF-positive samples, and the second run included all samples from the first run, with additional four CF-positive samples (Table [1](#Tab1){ref-type="table"}).Table 1Coverage statistics by samples.Run:1111Run 1 Average2222222222Run 2 AverageSample name:Sample 1Sample 2Sample 3Sample 4Sample 1Sample 2Sample 3Sample 4-1Sample 4-2Sample 4-3Sample 5Sample 6Sample 7Sample 8Read % on target:98.3298.3898.5198.3198.3899.2699.2499.2999.2699.2499.2199.2599.2099.2099.1499.23Mean coverage depth384540133598115535752992766168016471356147314051340143813441344% of targeted region \>20x100.00100.00100.00100.00100.0099.7399.7399.7399.7399.7399.7399.7199.7199.7199.7399.72Number of reads33824435159032145010190245075779068670252154784148982124390135350129530123800132844122072123269

Using the MiSeq Nano v2 kit, the sequencing coverage depth averages for run 1 (four samples) and run 2 (ten samples) are 5753x and 1344x, respectively, with almost 100% of the *CFTR* target region being more than 20x (Table [1](#Tab1){ref-type="table"}). As expected for amplicon sequencing, 98--99% of sequencing reads are on-target. We analysed the sequencing performance on the exon level. The coding region, 5′UTR and 3′UTR of the *CFTR* gene has 6123 bp, while the amplicon covers these regions with more than 3000 bp padded region (targeted amplicon size = 9666 bp), with additional amplicons covering four intronic regions (introns 1, 12, 22, and 25) (Table [2](#Tab2){ref-type="table"}). The number of amplicons for each exon correlates with the size of the exons (R^2^ = 0.9766%) (Fig. [1](#Fig1){ref-type="fig"}).Table 2Coverage statistics by exons.ExonLegacy exons\# of ampliconschromstartendamplicon sizeexon size%GC per exonMean coverage in run 1Mean coverage in run 25′UTR/exon 15′UTR/exon 13711711996211712027631518549.0661671614intron 1intron 11711713831611713839782n/an/a23361241exon 2exon 21711714428011714447019111141.441938318exon 3exon 32711714905311714931726510935.782649609exon 4exon 43711717088511717119330921643.06105232370exon 5exon 5271171742571171745472919034.442802677exon 6exon 6a2711717524211717552228116451.2295522095exon 7exon 6b2711717654711717678624012636.5138401087exon 8exon 74711718010611718046936424744.1362551518exon 9exon 8271171820011171822292299336.561558352exon 10exon 92711718864011718888124218338.82021377exon 11exon 102711719945611719973928419238.543458707exon 12exon 11171172277471172279141689542.1182581781intron 12intron 1127117229400117229594195n/an/a2062730exon 13exon 12271172303791172305521748728.742472685exon 14exon 138711723191411723275684372440.8880441770exon 15exon 14a3711723485611723517331812937.982200572exon 16exon 14b171172428411172429781382852.63104283268exon 17exon 153711724355411724388733425141.04112542708exon 18exon 16271172466321172468652348037.52422653exon 19exon 17a2711725054211725081327215139.073944901exon 20exon 17b3711725151711725199547922840.793318660exon 21exon 181711725460911725480419610142.573741691exon 22exon 194711726753911726788534725042.9772651831intron 22intron 191711727995011728004798n/an/a46771872exon 23exon 203711728246711728275528915644.8771791671exon 24exon 21271172927961172930762819032.222681510exon 25/intron 25exon 22/intron 223711730458611730496638117349.7190762349exon 26exon 232711730545811730579333610634.915435831exon 27/3′UTRexon 24/3′UTR1871173068911173087551865175852.2468761555Fig. 1Correlation of amplicon numbers and exon size. The numbers of amplicons for each exon is plotted against the exon size, except intron 1, 12, and 22. A trendline is plotted from the data and R^2^ is calculated to be 0.9766.

Using the manufacturer's recommended bioinformatic pipeline, we were able to detect all the mutations in the CF-positive samples. No pathogenic variants were detected in sample 1 (normal control) in both runs. Repeated samples in the inter- and intra-run analyses were found to be concordant (See technical validation section for more details).

Here, we provide the FASTQ files for each of the samples in this validation study. Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} provide the coverage summary for each sample and each exon. Furthermore, in the method and technical validation section, we describe the steps and quality control (QC) performed to ensure the accuracy and precision of the assay.

To our knowledge, no previous studies have critically evaluated the sequencing performance of the Accel-Amplicon CFTR panel. As analytical performance of the methodology is vital for a clinical test, the data generated in this study can be evaluated by clinical genetic laboratories that are interested in employing the Accel-Amplicon CFTR panel to screen CF carriers. As carrier screening becomes more well-known and consumer demand increases, this method fulfils the need of an affordable and time-sensitive approach to screen *CFTR* mutations in general population carrier screening with a maximum detection rate.

Methods {#Sec2}
=======

Validation samples acquisition and DNA quantification {#Sec3}
-----------------------------------------------------

The following DNA samples (samples 1--3, 5--8) were obtained from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical Research (see the corresponding Coriell naming convention in Table [3](#Tab3){ref-type="table"}). Sample 4 was acquired from a patient; an informed consent was obtained for research using an IRB protocol (06-004886) at the Center for Applied Genomics at the Children's Hospital of Philadelphia. The consent agreement states that genotype data may be shared with public data repositories for research purposes, and that the patient's personal information would be kept private and unidentifiable in any publication or presentation. DNA concentration was calculated using a Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific, catalogue number Q32851). Samples were diluted down to 5 ng/mL with Pre-PCR TE buffer and a final volume of 10 μL containing 20 ng input DNA was used.Table 3Sample manifest.Sample:Sample 1Sample 2Sample 3Sample 4Sample 5Sample 6Sample 7Sample 8*CFTR* Allele 1:n/ap.Arg117Hisc.489 + 1G \> Tp.Phe508delp.Ile507delc.2657 + 5G \> Ap.Arg1162Xc.3528delC*CFTR* Allele 2:n/ap.Phe508delc.579 + 1G \> Tn/an/ac.2657 + 5G \> An/ap.Phe508delCatalog Number:NA12878NA13591NA11280CF_Sample_4NA11277NA11859NA12585NA11275

Library preparation {#Sec4}
-------------------

Library preparation was performed using the Accel-Amplicon CFTR panel (Swift Bioscience, catalogue number AL-55048) in accordance with the manufacturer's protocol. In brief, multiplex PCR was performed on the sample DNA using the reagents provided by the Accel-Amplicon panel kit for 4 cycles of 10 sec at 98 °C, 5 min at 63 °C, 1 min at 65 °C and 22 cycles of 10 sec at 98 °C, 1 min at 64 °C. Size selection and clean-up were performed using SPRIselect beads (Beckman Coulter, catalogue number B23318) with a ratio of 1.2. Indexing sequencing adapters were then ligated to each library at 37 °C for 20 minutes. A second clean-up step was performed using SPRIselect beads at a ratio of 0.85 and rediluted with 20 mL of Post-PCR TE buffer. Quantification of adapted libraries was performed by qPCR using KAPA Library Quantification Kit (KAPA Biosystems, catalogue number 07960140001).

Next-generation sequencing {#Sec5}
--------------------------

Illumina MiSeq Nano Reagent Kit V2 was used to sequence the samples (Table [1](#Tab1){ref-type="table"}). The final pooled concentration of 2 nM (5 μL was used) was mixed with 0.2 N NaOH (5 μL). The mixture was then mixed with 990 μL of pre-chilled HT1 to obtained a 10 pM denatured library mixed. No PhiX spike-in was used.

Bioinformatic analysis {#Sec6}
----------------------

Sequencing data was analysed based on the bioinformatic pipeline recommended and provided by Swift Biosciences. In short, adapter-trimmed paired-end FASTQ files were generated by the Illumina MiSeq upon completion of the sequencing run (Note: adapter trimming can be done post FASTQ generation). For each sample, an alignment in Sequence Alignment Map (SAM) format was generated from the pair of FASTQ files using Burrows-Wheeler Aligner (BWA) and hg19 human genome reference. The SAM file was further modified by SAMtools to sort the file by name for Swift primerclip preparation. Due to the presence of synthetic primer sequences at the start or end of reads, the primerclip tool was used to remove these sequences before proceeding with downstream analysis. With both Picard's AddOrReplaceReadGroups tool and SAMtools, the primer-clipped SAM file was converted to BAM format and an indexed BAM file was generated. Variant calling was performed using GATK HaplotypeCaller. To determine quality metrics at the sample and interval level, Picard's CollectTargetPcrMetrics was used.

Sanger sequencing {#Sec7}
-----------------

Pathogenic variants were confirmed using Sanger sequencing. PCR was performed using QIAGEN Fast Cycling PCR kit (\#203743) with primers flanking the variants of interest (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). The PCR conditions were: 5 minutes at 95 °C, 35 cycles \[5 seconds at 96 °C, 5 seconds at 58 °C, 40 seconds at 68 °C\], 1 minute at 72 °C. PCR products were purified using Applied Biosystems ExoSAP-IT PCR Product Cleanup Reagent (\#78201.1.ML). Sequencing reactions were performed using Applied Biosystems BigDye Terminator v1.1 Cycle Sequencing Kit (\#4337449), and were purified using Applied Biosystem Centri-Seq. 8-Well Strips (\#4367820). Sanger sequencing was performed using Applied Biosystems 3500 Genetic Analyzer (\#4440462).Table 4Primer sequences for variant detection.Primer NameSequences (5′ to 3′)Variants detectedExon 4 FTGGCCACTATTCACTGTTTAACTTp.Arg117His; c.489 + 1G \> TExon 4 RGAGGCAGTTTACAGAAGATACTCAAExon 5 FTTGAAAGAAACATTTATGAACCTGAc.579 + 1G \> TExon 5 RCTATTATCTGACCCAGGAAAACTCExon 10 FCACTTCTGCTTAGGATGATAATTGGp.Ile507del; p.Phe508delExon 10 RCAGTAGCTTACCCATAGAGGAAACAExon 14b FCAGGAACACAAAGCAAAGGAAc.2657 + 5G \> AExon 14b RCAGGAATGTGTCACCTCACCExon 19 FTGAAAAGCCCGACAAATAACCp.Arg1162X; c.3528delCExon 19 RACTTGTTTGGCAGAATGGAACTable 5Sample file names as listed in SRA.SampleRun1Run21SRR8945290_1\_1.fastqSRR10164005_1\_1.fastqSRR8945290_1\_2.fastqSRR10164005_1\_2.fastq2SRR8945291_3\_1.fastqSRR8945291_2\_1.fastqSRR8945291_3\_2.fastqSRR8945291_2\_2.fastq3SRR8945292_4\_1.fastqSRR8945292_6\_1.fastqSRR8945292_4\_2.fastqSRR8945292_6\_2.fastq4SRR8945293_2\_1.fastqSRR8945293_3\_1.fastqSRR8945293_2\_2.fastqSRR8945293_3\_2.fastqSRR8945293_4\_1.fastqSRR8945293_4\_2.fastqSRR8945293_5\_1.fastqSRR8945293_5\_2.fastq5SRR8945286_7\_1.fastqSRR8945286_7\_2.fastq6SRR8945287_8\_1.fastqSRR8945287_8\_2.fastq7SRR8945288_9\_1.fastqSRR8945288_9\_2.fastq8SRR8945289_10_1.fastqSRR8945289_10_2.fastq

### BWA-MEM alignment {#Sec8}

bwa mem \${FASTA} \${Sample_ID}\_R1.fastq.gz \${Sample_ID}\_R2.fastq.gz -U 17 -M -t 32 \> \${Sample_ID}\_bwa.sam.

### SAMtools sort SAM {#Sec9}

samtools sort -n \${Sample_ID}\_bwa.sam -o \${Sample_ID}\_bwa_nsorted.sam.

### Primerclip {#Sec10}

primerclip Accel-Amplicon_CFTR_masterfile.txt \${Sample_ID}\_bwa_nsorted.sam \${Sample_ID}\_bwa_primertrimmed.sam.

### SAMtools convert SAM to BAM {#Sec11}

java -jar picard.jar AddOrReplaceReadGroups I=\${Sample_ID}\_bwa_primertrimmed.sam O=\${Sample_ID}\_bwa_primertrimmed.bam SO=coordinate RGID=snpID LB=swift SM=\${Sample_ID} PL=illumina PU=miseq VALIDATION_STRINGENCY=STRICT.

samtools index \${Sample_ID}\_bwa_primertrimmed.bam \${Sample_ID}\_bwa_primertrimmed.bam.bai.

### Picard CollectPcrMetrics tool {#Sec12}

samtools view -H \${Sample_ID}\_bwa_primertrimmed.bam \> \${Sample_ID}\_bwa_header.txt.

cat \${Sample_ID}\_bwa_header.txt cftr_180313_nonmerged_targets_5col.bed \> \${Sample_ID}\_bwa_fullintervals.

cat \${Sample_ID}\_bwa_header.txt cftr_180313_nonmerged_targets_5col.bed \> \${Sample_ID}\_bwa_noprimerintervals.

java -jar picard.jar CollectTargetedPcrMetrics I=\${Sample_ID}\_bwa_primertrimmed.bam O=\${Sample_ID}\_bwa_targetPCRmetrics.txt AI=\${Sample_ID}\_bwa_fullintervals TI=\${Sample_ID}\_bwa_noprimerintervals R=\${FASTA} PER_TARGET_COVERAGE=\${Sample_ID}\_bwa_perTargetCov.txt VALIDATION_STRINGENCY=STRICT.

### GATK variant calling {#Sec13}

java -jar GenomeAnalysisTK.jar -T HaplotypeCaller -R \${FASTA} -I \${Sample_ID}\_bwa_primertrimmed.bam -stand_call_conf 20 -stand_emit_conf 20 -mbq 20 -L CFTR_merged_5col.bed -o \${Sample_ID}\_bwa_gatkHC.vcf.

Data Records {#Sec14}
============

There are eight unique samples in our cohort. Samples 1--4 were analysed in both runs. Samples 5--8 were analysed in run 2. Sample 4 was run in triplicate in the second run. fastq can be accessed from the Sequence Read Archive (SRA) repository under SRA: SRP193469^[@CR13]^. Direct FASTQ files can be downloaded via SRA Toolkit using command line "fastq-dump--split-3 -G SRR\#" (Table [5](#Tab5){ref-type="table"}). BAM files can be downloaded at (10.6084/m9.figshare.11341958.v1), and VCF files can be downloaded at (10.6084/m9.figshare.10565513.v1)^[@CR14],[@CR15]^.

Technical Validation {#Sec15}
====================

Library quantitation {#Sec16}
--------------------

To evaluate whether the DNA samples were successfully processed using this Swift Accel Amplicon protocol, we used the KAPA Library Quantification Kit to measure the library concentration. During qPCR, primers bound to the Illumina P5 and P7 flow cell oligo sequences and the concentrations of the samples were assessed by measuring the SYBR green fluorescence intensity; this method specifically measures the adapted DNA, excluding any unadapted DNA fragments generated during the PCR step. The concentration of each sample in both runs are listed in Table [6](#Tab6){ref-type="table"}.Table 6Sequencing quality assessment.RunSampleConcentration (nM)Cluster Density (k/mm^2^)% Q301Sample 15.6807 ± 198.081Sample 24.51Sample 36.71Sample 42.62Sample 116.5534 ± 898.052Sample 214.62Sample 314.22Sample 4-114.52Sample 4-216.92Sample 4-316.02Sample 515.02Sample 619.12Sample 710.72Sample 812.5

Sequencing data assessment {#Sec17}
--------------------------

Pooled libraries were sequenced using Illumina MiSeq Nano Reagent Kit V2 kit (300 cycles). The cluster densities for run 1 and 2 were 807 ± 1 k/mm^2^ and 534 ± 8 k/mm^2^, with 98.08% and 98.05% of reads of Q30 score or more, respectively (Table [6](#Tab6){ref-type="table"}). Further analyses of the FASTQ files using MultiQC showed that the majority of the base positions had mean quality value of Q38, while the first five bases of reads have lower quality scores (at around Q33) (Fig. [2a](#Fig2){ref-type="fig"}). For all FASTQ files, the majority of the reads had quality value of Q38 (Fig. [2b](#Fig2){ref-type="fig"})^[@CR16]^. Overall coverage depth of all processed samples is demonstrated in Table [1](#Tab1){ref-type="table"}. As expected, the mean coverage depth in run 1 (5753x) is higher than those of run 2 (1344x), as there are fewer samples pooled into one flow cell in run 1 (Table [1](#Tab1){ref-type="table"}). Moreover, all samples from run 1 have 100% of regions with more than 20x coverage depth (Table [1](#Tab1){ref-type="table"}). For run 2, all samples have less than 20x coverage at the 3′UTR region (chr7:117308320--117308346; CFTR:c.\*1158\_\*1184). This region has no known pathogenic variants described in HGMD or in ClinVar. In addition, samples 5, 6, and 7 have no coverage for two bases in intron 8 (chr7:117188661--117188662; CFTR:c.1210-13_1210-12). This is a common TG repeat deletion that is present in 22.92% of general population according to gnomAD. Next, we assessed the coverage depth per exon, and investigated the inter-exonic depth variability (Tables [2](#Tab2){ref-type="table"} and [7](#Tab7){ref-type="table"}). We found that the coverage depth was higher as the GC content of the exon was closer to 50% for both runs (Fig. [2c,d](#Fig2){ref-type="fig"}). As expected for amplicon sequencing, the majority of sequencing reads (98--99%) were aligned to the targeted regions (See Supplementary File [1](#MOESM1){ref-type="media"} for BED file).Fig. 2Sequence quality and coverage depth per exon. Sequence quality was assessed using MultiQC. Each green line represents one FASTQ file. (**a**) Mean quality value across each base position in the read. (**b**) Number of reads with average quality score. (**c**,**d**) For both runs, the coverage depth of exons increases as the GC content approaches 50%.Table 7Sequencing coverage depth per exon for each sample.Run:11112222222222Swift exon annotationSample 1Sample 2Sample 3Sample 4Sample 1Sample 2Sample 3Sample 4Sample 4Sample 4Sample 5Sample 6Sample 7Sample 85′UTR/exon 137284312400412623119389819531729152018681886166219021525intron 11424123519124771101173415841228126114261415123513681146exon 2136713599584068208181395352331463289311287363exon 31737215015365175476382705636628761637653616597exon 4683669436411219021756129528652555236529202630240325962312exon 51857191215235914508398756766739944627636685713exon 6647763725699196621524113625022250214627302139206322212242exon 7259022582304820875861613381149121514351074110610441136exon 841094346378612778115882418271703154018481622160316571393exon 9106110389593174264204477441351479334347316304exon 101384166412173817283192451442423469374412416307exon 112434251218647022547394828840807907712634741664exon 12580657384783167031232102622021874178824461716177317761974intron 121404143414963916573415884797708901750775768726exon 131703174715824855511346872786695857674663703746exon 14550759975398152721288101022561799166019751987185119981880exon 151551167013704210417324747625609699570587604536exon 16707561917432210162308202842773478328339843353290934623600exon 17777881377004220962029154234882881255131032926277730212763exon 181652168114854868488371757735691824667676704621exon 1926592826211781746465201082103189610299718851021930exon 202298238519946595461382812748686825635644685725exon 212556275019697690490367798788731888632697651871exon 22474950514783144771400108822482067198921561841187819491689intron 2228442607336098951500111722812157190823541980182619541641exon 2346204976432514794130497221031932176620611702160716911575exon 241739212615335327385302615568521659515485543511exon 25/intron 25592261585744184821761131829922695233829062521222324682266exon 263775404030411088462645898810389691152730799780774exon 27/3′UTR45554687442513837112689620091702156019251602152716621539

Assay validation of CF-positive samples {#Sec18}
---------------------------------------

Samples used in this validation study have known pathogenic *CFTR* mutations (Table [3](#Tab3){ref-type="table"}), and they were used to validate this Swift Accel-Amplicon CFTR Panel for usage in a clinical laboratory setting. Analytical validation is a vital component in the process of launching a clinical genetic test, as it demonstrates the quality and performance of the testing method and the accuracy of the assay result. Here, we evaluate the capability of this assay by assessing the variants that were detected in each sample. As expected, there were no pathogenic variants detected in the control sample (sample 1) for both runs. The pathogenic variants of samples 2--8 were confirmed by the manufacturer-recommended bioinformatic pipeline. These genotypes can be visualized using Integrative Genome Viewer (IGV), and they have also been confirmed using Sanger sequencing (Fig. [3](#Fig3){ref-type="fig"}); this yields a 100% sensitivity. Furthermore, samples 1--4 were sequenced in both runs, and sample 4 was sequenced three times in run 2. All results were concordant and matched to the referenced genotypes, hence the repeatability and reproducibility is 100%. Additionally, since there can be non-pathogenic variants in *CFTR*, we provide a table of all the variants detected in each VCF file for each sample in both run (Online-only Table [1](#Tab8){ref-type="table"}). HGVS nomenclature and GnomAD frequencies for each variant are also listed. Of note, the VCF for sample 1 in run 2 contains a variant that is not present in run 1. This variant is a common two-nucleotide deletion of a TG-repeat stretch in intron 8. This dinucleotide repeat is adjacent to a poly-T stretch that also has common deletions and duplications. This discrepancy may be due to the fact that NGS alignment and annotation tools cannot reliably detect small insertions/deletions at repetitive regions. Sanger sequencing is still the preferred method to reliably detect variants at this repeat.Fig. 3Variant visualization using IGV and Mutation Surveyor. The variants for each corresponding sample are confirmed by visualizing the BAM files in Integrative Genomic Viewer (IGV). The Sanger sequence traces visualized using MutationSurveyor are also shown for each variant of each sample.

Supplementary information {#Sec20}
-------------------------

Supplementary File 1

Online-only Table {#Sec19}
=================

Online-only Table 1Variants listed in each VCF file for each sample.RunSampleChromPOSIDRefAltNomenclatureGnomad Freq127117120145.GCc.-4G \> C0.00007433127117171029.GAc.350G \> A0.001438127117176568.AGATTAc.744-9_744-6del0.2648127117176738.CTc.869 + 11C \> T0.06933127117188682.GTc.1210-13G \> T0.0752127117188684.TGc.1210-11T \> G0.008495127117199457.AGc.1393-61A \> G0.267127117199533.GAc.1408G \> A0.4865127117199644.ATCTAc.1521_1523del0.007172127117229537.TAc.1680-870T \> A0.5654137117171169.GTc.489 + 1G \> T0.00006857137117174420.GTc.579 + 1G \> T0.0000462137117176568.AGATTAc.744-9_744-6del0.2648137117176738.CTc.869 + 11C \> T0.06933137117188682.GTc.1210-13G \> T0.0752137117199457.AGc.1393-61A \> G0.267137117199533.GAc.1408G \> A0.4865137117229537.TAc.1680-870T \> A0.5654137117307286.GTGc.\*133del0.4942147117176568.AGATTAc.744-9_744-6del0.2648147117176738.CTc.869 + 11C \> T0.06933147117188682.GTc.1210-13G \> T0.0752147117199457.AGc.1393-61A \> G0.267147117199533.GAc.1408G \> A0.4865147117199644.ATCTAc.1521_1523del0.007172147117229537.TAc.1680-870T \> A0.5654147117246636.GAc.2909-92G \> A0.1755147117307108.GAc.4389G \> A0.2206147117307286.GTGc.\*133del0.4942147117308413.CTc.\*1251C \> T0.2566217117188660.ATGAc.1210-13_1210-12del0.2292227117120145.GCc.-4G \> C0.00007433227117171029.GAc.350G \> A0.001438227117176568.AGATTAc.744-9_744-6del0.2648227117176738.CTc.869 + 11C \> T0.06933227117188682.GTc.1210-13G \> T0.0752227117188684.TGc.1210-11T \> G0.008495227117199457.AGc.1393-61A \> G0.267227117199533.GAc.1408G \> A0.4865227117199644.ATCTAc.1521_1523del0.007172227117229537.TAc.1680-870T \> A0.5654237117171169.GTc.489 + 1G \> T0.00006857237117174420.GTc.579 + 1G \> T0.0000462237117176568.AGATTAc.744-9_744-6del0.2648237117176738.CTc.869 + 11C \> T0.06933237117188682.GTc.1210-13G \> T0.0752237117199457.AGc.1393-61A \> G0.267237117199533.GAc.1408G \> A0.4865237117229537.TAc.1680-870T \> A0.5654237117307286.GTGc.\*133del0.494224-17117176568.AGATTAc.744-9_744-6del0.264824-17117176738.CTc.869 + 11C \> T0.0693324-17117188682.GTc.1210-13G \> T0.075224-17117199457.AGc.1393-61A \> G0.26724-17117199533.GAc.1408G \> A0.486524-17117199644.ATCTAc.1521_1523del0.00717224-17117229537.TAc.1680-870T \> A0.565424-17117246636.GAc.2909-92G \> A0.175524-17117307108.GAc.4389G \> A0.220624-17117307286.GTGc.\*133del0.494224-17117308413.CTc.\*1251C \> T0.256624-27117176568.AGATTAc.744-9_744-6del0.264824-27117176738.CTc.869 + 11C \> T0.0693324-27117188682.GTc.1210-13G \> T0.075224-27117199457.AGc.1393-61A \> G0.26724-27117199533.GAc.1408G \> A0.486524-27117199644.ATCTAc.1521_1523del0.00717224-27117229537.TAc.1680-870T \> A0.565424-27117246636.GAc.2909-92G \> A0.175524-27117307108.GAc.4389G \> A0.220624-27117307286.GTGc.\*133del0.494224-27117308413.CTc.\*1251C \> T0.256624-37117176568.AGATTAc.744-9_744-6del0.264824-37117176738.CTc.869 + 11C \> T0.0693324-37117188682.GTc.1210-13G \> T0.075224-37117199457.AGc.1393-61A \> G0.26724-37117199533.GAc.1408G \> A0.486524-37117199644.ATCTAc.1521_1523del0.00717224-37117229537.TAc.1680-870T \> A0.565424-37117246636.GAc.2909-92G \> A0.175524-37117307108.GAc.4389G \> A0.220624-37117307286.GTGc.\*133del0.494224-37117308413.CTc.\*1251C \> T0.2566257117188660.ATGTGA,ATGc.1210-13_1210-12del0.2292257117199533.GAc.1408G \> A0.4865257117199640.TATCTc.1519_1521del0.00004246257117229536.AGc.1680-871A \> G0.01043257117229537.TAc.1680-870T \> A0.5654257117235055.TGc.2562T \> G0.3901257117246636.GAc.2909-92G \> A0.1755257117307108.GAc.4389G \> A0.2206257117307286.GTGc.\*133delT0.4942257117308413.CTc.\*1251C \> T0.2566267117188660.ATGTGA,ATGc.1210-13_1210-12del0.2292267117199533.GAc.1408G \> A0.4865267117229537.TAc.1680-870T \> A0.5654267117235055.TGc.2562T \> G0.3901267117242922.GAc.2657 + 5 G \> A0.0000707267117246636.GAc.2909-92 G \> A0.1755267117307108.GAc.4389G \> A0.2206267117307286.GTGc.\*133delT0.4942267117308413.CTc.\*1251C \> T0.2566277117188660.ATGAc.1210-13_1210-12del0.2292277117199533.GAc.1408G \> A0.4865277117229537.TAc.1680-870T \> A0.5654277117235055.TGc.2562T \> G0.3901277117246636.GAc.2909-92G \> A0.1755277117267591.CTc.3484C \> T0.00005674277117307108.GAc.4389G \> A0.2206277117307286.GTGc.\*133del0.4942277117308413.CTc.\*1251C \> T0.2566287117176568.AGATTAc.744-9_744-6del0.2648287117176738.CTc.869 + 11C \> T0.06933287117188682.GTc.869 + 11C \> T0.06933287117199457.AGc.1393-61A \> G0.267287117199533.GAc.1408G \> A0.4865287117199644.ATCTAc.1521_1523del0.007172287117229537.TAc.1680-87 T \> A0.5654287117267633.ACAc.3528del0.0001559

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
=========================

is available for this paper at 10.1038/s41597-019-0339-4.

Sequencing and analyses in this study were supported by the Center for Applied Genomics at the Children's Hospital of Philadelphia. The authors thank Drew McUsic for his technical assistance.

M.L.L. analysed the data, designed and supervised the study, and wrote the manuscript. F.M. performed the experiments and wrote the method session of the manuscript. C.V. and A.W. performed the bioinformatic analysis and wrote the bioinformatic analysis session of the article. A.W. performed the bioinformatic analysis. D.W. analysed the data and wrote the manuscript. T.W. performed the experiments. H.H. and A.S. supervised the study.

Swift Primerclip installation instructions, scripts, and examples can be found at <https://github.com/swiftbiosciences/primerclip>. Current available methods for downloading the Swift Primerclip tool are a pre-compiled binary for linux on x86_64 and building from source using Haskell-stack build tool. Additional requirements include SAMTools (1.6-2-gf068ac2), Picard Tools (2.1.0), BWA (0.7.17-r1188), GATK (3.5-0-g36282e4), and Java (1.8). Codes and parameters are described as below.

The authors declare no competing interests.
